Online Supplement - Table 1. Selection of source and study populations

Inclusion/Exclusion Criteria	Total Population	
	n	%
Source Population		
Receipt of chemotherapy with myelosuppressive regimen from 1/2010 thru 12/2016	894,205	100.0%
Continuously enrolled for ≥6 months prior to initiation of chemotherapy	703,331	78.7%
Aged ≥18 years	686,615	76.8%
Evidence of single non-metastatic solid cancer or NHL	369,215	41.3%
No stem cell/bone marrow transplantation	361,526	40.4%
Study Population		
Receipt of intermediate/high-risk chemotherapy regimen for cancer of interest	142,730	100.0%
Non-metastatic breast: TC, TAC, TCH, dose-dense AC/AC-T	87,003	61.0%
Non-metastatic colorectal: FOLFOX	19,816	13.9%
Non-metastatic lung: carboplatin + paclitaxel	6,589	4.6%
NHL: CHOP/CHOP-R	15,620	10.9%
Non-metastatic ovarian: carboplatin + paclitaxel	13,702	9.6%
Study Population, by Calendar Quarter of Chemotherapy		
Overall	142,730	100.0%
2010		
Q1	5,721	4.0%
Q2	5,570	3.9%
Q3	6,271	4.4%
Q4	5,727	4.0%
2011		
Q1	5,990	4.2%
Q2	5,436	3.8%
Q3	6,511	4.6%
Q4	6,279	4.4%
2012	-, -	
Q1	6,497	4.6%
Q2	6,053	4.2%
Q3	6,109	4.3%
Q4	6,258	4.4%
2013	5,255	
Q1	5,399	3.8%
Q2	5,248	3.7%
Q3	5,685	4.0%
Q4	5,489	3.8%
2014	3,403	3.070
Q1	5,201	3.6%
Q2	4,691	3.3%
Q3	5,287	3.7%
Q4	4,970	3.7%
2015	4,370	3.370
Q1	3,874	2.7%
Q2	3,635	2.5%
Q3	3,768	2.6%
Q4	3,604	2.5%
2016	2.502	2.50/
Q1	3,503	2.5%
Q2	3,299	2.3%
Q3	3,504	2.5%
Q4	3,151	2.2%